Information
-
Trademark
-
97730282
-
International Classifications
-
Filing Date
December 23, 2022
a year ago
-
Transaction Date
April 09, 2024
5 months ago
-
Status Date
April 09, 2024
5 months ago
-
Published for Opposition Date
February 13, 2024
7 months ago
-
Location Date
April 09, 2024
5 months ago
-
Status Code
688
-
Current Location
INTENT TO USE SECTION
Employee Name
KOPENSKI, CLAUDIA ANN
-
Attorney Docket Number
00161757-US
Attorney Name
Marilyn F. Kelly
Law Office Assigned Location Code
O20
-
Owners
Mark Drawing Code
4000
Mark Identification
CELROSFI
Case File Statements
- GS0051: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Case File Event Statements
-
4/9/2024 - 5 months ago
14 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Type: NOAM
-
2/13/2024 - 7 months ago
13 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
2/13/2024 - 7 months ago
12 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
1/24/2024 - 8 months ago
11 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
1/8/2024 - 8 months ago
10 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
12/15/2023 - 9 months ago
9 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
12/14/2023 - 9 months ago
8 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
12/14/2023 - 9 months ago
7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
9/26/2023 - a year ago
6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
9/26/2023 - a year ago
5 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
9/26/2023 - a year ago
4 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
9/23/2023 - a year ago
3 - ASSIGNED TO EXAMINER
Type: DOCK
-
12/29/2022 - a year ago
2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS
-
12/27/2022 - a year ago
1 - NEW APPLICATION ENTERED
Type: NWAP